Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03324581
Other study ID # 277-201-00001
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 9, 2017
Est. completion date October 31, 2018

Study information

Verified date September 2021
Source Otsuka Pharmaceutical Development & Commercialization, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A trial to assess the safety and efficacy of OPC-64005 in the treatment of adult attention-deficit/hyperactivity disorder.


Description:

A multicenter, randomized, double-blind, active- and placebo-controlled, parallel-design trial.


Recruitment information / eligibility

Status Completed
Enrollment 239
Est. completion date October 31, 2018
Est. primary completion date October 31, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria (Screening): - Male and female participants 18 to 55 years of age, inclusive, at the time of informed consent. - Participants with a primary Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) diagnosis of ADHD (including predominantly inattentive presentation, hyperactive presentation, and combined presentations) as confirmed by the Adult ADHD Clinical Diagnostic Scale (ACDS) v 1.2. - Participants willing to discontinue all prohibited psychotropic medication starting from the time of signing the informed consent and up to the 30 (+ 2)-day follow-up period. Exclusion Criteria: - Participants with a history of inadequate response or suboptimal tolerability to atomoxetine. - Participants who report allergies (lifetime treatment history) to stimulant or nonstimulant ADHD medications. - Participants with other DSM-5 disorders including psychosis (current or lifetime), bipolar disorder (current or lifetime), current major depressive disorder, or current panic disorder; or another psychiatric diagnosis that the investigator believes is primary or that will confound efficacy or safety assessments of the trail or interfere with participation in the trial otherwise. - Participants with a clinically significant current DSM-5 diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, histrionic, narcissistic, avoidant, obsessive compulsive, or dependent personality disorders. - Participants who currently have clinically significant dermatological, neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorders such as any history of myocardial infarction, congestive heart failure, HIV (human immunodeficiency virus) seropositive status/acquired immunodeficiency syndrome, or active or chronic hepatitis B or C. - Participants with a history of obstructive sleep apnea.

Study Design


Related Conditions & MeSH terms

  • Adult Attention Deficit Hyperactivity Disorder
  • Attention Deficit Disorder with Hyperactivity
  • Hyperkinesis

Intervention

Drug:
OPC-64005
OPC-64005 film coated tablets
Atomoxetine
Atomoxetine gelatin capsules
Placebo
OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules

Locations

Country Name City State
United States Southern California Research, LLC Beverly Hills California
United States Meridien Research Bradenton Florida
United States MCB Clinical Research Centers, LLC Colorado Springs Colorado
United States iResearch Atlanta Decatur Georgia
United States Collaborative Neuroscience Network, LLC Garden Grove California
United States Clinical Neuroscience Solutions, Inc Jacksonville Florida
United States Center for Psychiatry and Behavioral Medicine Inc. Las Vegas Nevada
United States Innovative Clinical Research, Inc. Lauderhill Florida
United States BTC of Lincoln Lincoln Rhode Island
United States Premier Psychiatric Research Institute, LLC Lincoln Nebraska
United States Northwest Behavioral Research Center Marietta Georgia
United States Eastside Comprehensive Medical Center, LLC. New York New York
United States The Medical Research Network, LLC New York New York
United States Behavioral Clinical Research, Inc. North Miami Florida
United States IPS Research Company Oklahoma City Oklahoma
United States Paradigm Research Professionals Oklahoma City Oklahoma
United States Aspen Clinical Research Orem Utah
United States Clinical Neuroscience Solutions Inc. Orlando Florida
United States Clinical Neuroscience Solutions, Inc. Orlando Florida
United States Psychiatric Associates Overland Park Kansas
United States Oregon Center for Clinical Investigators, Inc. Portland Oregon
United States Oregon Center for Clinical Investigators, Inc. Salem Oregon
United States Clinical Trials of Texas, Inc. San Antonio Texas
United States Artemis Institute for Clinical Research San Diego California
United States Artemis Institute for Clinical Research San Marcos California
United States Neuropsychiatric Associates Woodstock Vermont

Sponsors (1)

Lead Sponsor Collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change From Baseline in CAARS-O:SV 18-item Score on Days 7, 14, 21, 28, 42, and 56 The investigator-administered CAARS-O:SV consists of 18 items based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. It includes a 9-item inattentive symptom subscale and a 9- item hyperactive and impulsive symptoms subscale. Each item is rated on a scale of 0 to 3 where 0=not at all, never; 1=just a little, once a while; 2=pretty much, often; and 3=very much, very frequently. The score for each subscale can range from 0 to 27. The total score is the sum of individual scores and can range from 0 to 54. Higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. Baseline, Days 7, 14, 21, 28, 42, and 56
Other Change From Baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) With Adult Prompts Score on Day 28 and Day 56 The AISRS consists of 18-items derived from DSM-IV criteria for ADHD symptoms. The AISRS total score is the sum of the 9-item inattentive symptoms subscale and 9-item hyperactive and impulsive symptoms subscale. Each item is scored as follows: 0=none, 1=mild, 2=moderate, and 3=severe. The score for each subscale can range from 0 to 27. The total score can range from 0 to 54. A negative change from Baseline indicates improvement. Baseline, Days 28 and 56
Other Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score on Days 7, 14, 21, 28, 42, and 56 The CGI-S evaluates the severity of individual symptoms and treatment response in participants with mental disorders. It is a 7-point scale that that requires the clinician to rate the severity of the participant's illness at the time of assessment as 0=not assessed, 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill participants. The score 0=not assessed was set to missing. A negative change from Baseline indicates improvement. Baseline, Days 7, 14, 21, 28, 42, and 56
Other Clinical Global Impression-Improvement (CGI-I) Score on Days 7, 14, 21, 28, 42, and 56 The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a Baseline state at the beginning of the intervention and rated as: 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. The score of 0 =not assessed was set to missing. Lower scores indicate improvement. Baseline, Days 7, 14, 21, 28, 42, and 56
Other Change From Baseline in Conners' Adult ADHD Rating Scales-Self-Report: Screening Version (CAARS-S:SV) 18-item Total Score on Days 7, 14, 21, 28, 42, and 56 The CAARS-S:SV comprises of 30 items to measure symptoms for ADHD in adults but was limited to the 18 DSM-5 criteria relevant items for this trial. The 18-item ADHD Symptoms total score is the sum of the 9-item inattentive symptoms subscale and the 9-item hyperactive and impulsive symptoms subscale. Each item is rated on a scale of 0 to 3 where 0=not at all, never; 1=just a little, once a while; 2=pretty much, often; and 3=very much, very frequently. The score for each subscale can range from 0 to 27. Total score can range from 0 to 54. A negative change from Baseline indicates improvement. Baseline, Days 7, 14, 21, 28, 42, and 56
Other Change From Baseline in Adult ADHD Quality of Life Scale (AAQoL) Total Score on Day 28 and Day 56 The AAQoL is a validated, 29-item instrument for measuring the impact of ADHD symptoms on quality of life. The scale assesses 4 distinct functional domains based on the following subscales: life productivity (11 items), psychological health (6 items), life outlook (7 items), and relationships (5 items). Scores for individual items range from 1=never/not at all to 5=extremely/very often. Total and subscale scores were computed by (1) reversing scores for all items except the seven items in the Life Outlook subscale; (2) transforming all item scores to a 0-100 point scale (1=0; 2=25; 3=50; 4=75; 5=100); and (3) summing item scores and dividing by the item count to generate subscale and total scores. Higher scores indicate a greater impact. Baseline, Days 28, and 56
Other OPC-64005 Potential for Abuse Liability and Dependence as Assessed by the Drug Effects Questionnaire (DEQ) Score The DEQ was used to assess the potential for abuse of OPC-64005. It is a 5-item questionnaire completed by the participant that includes the following questions: 1. Do you feel a drug effect right now? 2. Are you high right now? 3. Do you dislike any of the effects you are feeling right now? 4. Do you like any of the effects you are feeling right now? 5. would you like more of the drug you took, right now? Each item is rated on a 100-point scale of 1 (not at all) to 100 (extremely). 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome. Baseline, Days 7, 14, 21, 28, 42, and 56
Primary Change From Baseline in Conners' Adult ADHD Rating Scales-Observer: Screening Version (CAARS-O:SV) 18-item ADHD Symptoms Total Score at Day 56 The investigator-administered CAARS-O:SV consists of 18 items based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). It includes a 9-item inattentive symptom subscale and a 9-item hyperactive and impulsive symptoms subscale. Each item is rated on a scale of 0 to 3 where 0=not at all, never; 1=just a little, once a while; 2=pretty much, often; and 3=very much, very frequently. The score for each subscale can range from 0 to 27. The total score is the sum of individual scores and can range from 0 to 54. Higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. Baseline, Day 56
See also
  Status Clinical Trial Phase
Recruiting NCT06000501 - Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening Phase 4
Completed NCT03721588 - Clinical and Suicidal Features of Urban, Turkish Middle Age Depressive Patients With Comorbid ADHD
Active, not recruiting NCT06221930 - Researching the Effectiveness of Attexis, a Digital Health Application for Adults With Attention Deficit Hyperactivity Disorder N/A
Completed NCT02160262 - Open-label Safety Study in Adults With ADHD Phase 3
Completed NCT02276209 - Dasotraline Adult ADHD Study Phase 3
Completed NCT01798381 - Essential Fatty Acids in Adult ADHD Phase 3
Completed NCT01692782 - Adult Attention Deficit Hyperactivity Disorder Phase 2
Completed NCT00553319 - Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence Phase 2/Phase 3